CD248

Across TCGA pan-cancer cohorts, CD248 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CD248 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher CD248 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD248 expression acts as an unfavorable survival marker.

PAAD, LUAD, and BLCA are the cancer types where CD248 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.011	0.641	<.001	12	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	12	view →
BLCA	OS	Median	All	0.217	0.618	.026	9	view →
COAD	DFS	Median	All	0.105	0.559	.006	6	view →
PRAD	DFS	Median	All	0.107	0.886	<.001	6	view →
LUSC	OS	Median	All	0.192	0.724	.040	3	view →
SKCM	DFS	Median	II,III,IV	0.192	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CD248–PAAD (OS)

Open the PAAD breakdown →